Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roxadustat versus darbepoetin alfa for anemia in non-dialysis chronic kidney disease
NL-OMON45044Phase 3Active, not recruiting
- Sponsor
- Astellas Pharma
- Start
- Oct 2014
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of roxadustat and darbepoetin alfa in Uraemic Anaemia (4 arms), sponsored by Astellas Pharma. Primary endpoint: Primary efficacy endpoint. Started Oct 2014; status: active, not recruiting.
02
Drugs
roxadustatdarbepoetin alfa
03
Conditions
Uraemic Anaemia
Beyond the preview
Go deeper on NL-OMON45044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45044.